CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccine +1 morebiological
Likely dose
13-valent Pneumococcal Conjugate Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00824850
NCT00824850Phase 2Completed
CompareCT.gov

Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort

Pfizer·interventional·Posted Jan 19, 2009·Updated Nov 11, 2011

In Brief

A Phase 2 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine for Pneumococcal Conjugate Vaccine. Completed, enrolled 75 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Conjugate Vaccine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2009
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.5 years ago

Interventions

13-valent Pneumococcal Conjugate Vaccinebiological

single injection, single dose, single site, 0.5 mL per dose.

13-valent Pneumococcal Conjugate Vaccinebiological

single injection, single dose, single site, 0.5 mL per dose.